Proton pump inhibitors (PPIs) are extensively used in clinical practice because of their effectiveness and safety in humans.
The glycolytic enzyme triosephosphate isomerase from Giardia lamblia (GlTIM) is a good target to generate antigiardiasic drugs.
All the proton pump inhibitors efficiently inactivate and desestabilizate the GlTIM at functional and structural levels.
Rabeprazole represents a promising lead in the search of new antigiardiasic drugs.
The mechanisms of action of the PPIs on GlTIM can be helpful to understand their effectiveness and safety in human.